Skip to main content

Table 3 Anti-c-Met therapies currently under investigation in clinical trials for breast cancer [11]

From: The clinical and functional significance of c-Met in breast cancer: a review

Compound Target/mechanism of action ClinicalTrials.gov identifier
Tivantinib (ARQ197) c-Met/non-ATP kinase inhibitor NCT 01575522
Cabozantinib (XL184) c-Met and VEGFR, along with RET, KIT, AXL/kinase inhibitor NCT 01738438
Foretinib (XL880) c-Met and VEGFR, along with KIT, Flt-3, PDGFR, Tie-2/kinase inhibitor NCT 01147484
MetMab (onartuzumab) c-Met/anti-c-Met antibody NCT 01186991
  1. PDGFR, platelet-derived growth factor receptor; VEGFR, vascular endothelial growth factor receptor.